Rivaroxaban: 2034 patent, 19 approved ANDAs | Phontix AI
Orange Book lists patent 9,539,218 on Xarelto 10, 15 and 20 mg to Feb 2034 (Aug 2034 with pediatric entry). FDA shows 19 approved generic applications.
Read MoreResearch library
Articles
Evidence-led explainers and research on the markets we track.
8 resources · Page 1 of 1
Denosumab biosimilars: the US launch queue and Amgen's sales
US denosumab biosimilars entered from 2 June 2025 on reported settlement dates. Amgen's global Prolia sales fell 33% and Xgeva 31% in H1 2026.
Read MoreEliquis generics: 1 April 2028 is not an Orange Book date
In 2021 the Bristol Myers Squibb-Pfizer Alliance gave 1 April 2028 as the earliest US generic date, subject to appeals. The Orange Book lists other dates.
Read MoreEU Bisphenol A Food-Contact Ban, Deadline by Deadline
Regulation 2024/3190 sets four dates for BPA in EU food contact materials. Which one applies depends on the article and when it was first placed.
Read MoreIndia's Epoxy Resin Duty: What Changed
India's anti-dumping duty on liquid epoxy resin began in November 2025. Customs data shows imports level and the origin mix changed. What a buyer can do.
Read MoreIndia's Phenol Anti-Dumping Case: Seven Origins
DGTR's phenol anti-dumping case names seven origins. Customs data shows who supplied India in FY2025-26 and January to July 2026, and what a buyer can do.
Read MoreKeytruda Loss of Exclusivity: IV vs Qlex Dates
Merck lists US patent expiry for IV Keytruda at 2028 and Keytruda Qlex at 2043. Qlex is a separate FDA licence, BLA 761467. Sources read 15 to 23 Oct 2026.
Read MoreVedolizumab biosimilars: US lawsuits and London claims
Takeda has sued two vedolizumab biosimilar developers in New Jersey on six patents. Google Patents puts their anticipated expiry at 2 May 2032.
Read MoreNo resources match these filters. Try another topic or search.